Details:
This open-label, phase 1/2 study of melflufen and dexamethasone for patients with AL amyloidosis, following at least one prior line of therapy, is the first study to explore the effect of melflufen outside of multiple myeloma.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Rare Diseases and Disorders Product Name: Melflufen
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020